DAFNA Capital Management LLC - Q2 2014 holdings

$106 Million is the total value of DAFNA Capital Management LLC's 49 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 0.0% .

 Value Shares↓ Weighting
ATRC  ATRICURE INC$10,495,000
-2.3%
570,9870.0%9.95%
+7.7%
DSCO  DISCOVERY LABORATORIES INC$10,144,000
-17.2%
5,698,7390.0%9.61%
-8.7%
NXTM  NXSTAGE MEDICAL INC$5,520,000
+12.8%
384,1540.0%5.23%
+24.4%
STXS  STEREOTAXIS INC$4,904,000
-16.5%
1,381,4600.0%4.65%
-7.9%
DSCI  DERMA SCIENCES INC$4,448,000
-8.8%
384,7940.0%4.22%
+0.5%
NVDQ  NOVADAQ TECHNOLOGIES INC$4,343,000
-26.0%
263,5410.0%4.12%
-18.4%
PODD  INSULET CORP$4,341,000
-16.3%
109,4180.0%4.11%
-7.8%
PLX  PROTALIX BIOTHERAPEUTICS INC$4,301,000
-20.3%
1,178,4400.0%4.08%
-12.1%
BOTA  BIOTA PHARMACEUTICALS INC$2,080,000
-53.4%
729,7810.0%1.97%
-48.6%
BSTC  BIOSPECIFICS TECHNOLOGIES$1,890,000
+4.0%
70,0880.0%1.79%
+14.7%
 NUVASIVE INCnote 2.750% 7/0$1,146,000
-4.0%
1,000,0000.0%1.09%
+5.8%
JNJ  JOHNSON AND JOHNSON$983,000
+6.5%
9,4000.0%0.93%
+17.5%
SPNC  SPECTRANETICS CORP$965,000
-24.5%
42,1620.0%0.92%
-16.7%
CYTR  CYTRX CORP$941,000
+19.9%
225,0000.0%0.89%
+32.1%
ELOS  SYNERON MEDICAL LTD$939,000
-17.0%
90,9470.0%0.89%
-8.5%
CUTR  CUTERA INC$922,000
-7.1%
88,6940.0%0.87%
+2.5%
EXAC  EXACTECH INC$798,000
+11.9%
31,6360.0%0.76%
+23.3%
RTIX  RTI SURGICAL INC$727,000
+6.6%
167,0580.0%0.69%
+17.6%
ICPT  INTERCEPT PHARMACEUTICALS IN$473,000
-28.3%
2,0000.0%0.45%
-21.0%
LPTN  LPATH INC$417,000
-16.4%
105,0000.0%0.40%
-7.9%
MASI  MASIMO CORPORATION$413,000
-13.6%
17,5000.0%0.39%
-4.9%
TNXP  TONIX PHARMACEUTICALS HLDG C$359,000
+38.1%
25,0000.0%0.34%
+52.5%
CRIS  CURIS INC$279,000
-34.0%
150,0000.0%0.26%
-27.5%
CLTX  CELSUS THERAPEUTICS PLCsponsored adr ne$272,000
-4.6%
43,9000.0%0.26%
+5.3%
GNVC  GENVEC INC$257,000
-3.0%
100,0000.0%0.24%
+7.0%
CEMI  CHEMBIO DIAGNOSTICS INC$189,000
-0.5%
55,2020.0%0.18%
+9.8%
RVP  RETRACTABLE TECHNOLOGIES INC$50,000
-34.2%
20,0000.0%0.05%
-27.7%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STEREOTAXIS INC42Q3 202327.6%
ATRICURE INC42Q3 202311.4%
MASIMO CORPORATION42Q3 20231.8%
ASCENDIS PHARMA A S SPONSORED34Q3 20234.5%
AERIE PHARMACEUTICALS INC33Q3 20224.2%
GALAPAGOS NV-SPON ADR33Q3 20233.8%
XENON PHARMACEUTICALS INC33Q3 20233.6%
NEUROCRINE BIOSCIENCES INC32Q3 20232.9%
JOHNSON AND JOHNSON32Q1 20211.2%
ISHARES TR NASDQ BIOTECH30Q3 20234.0%

View DAFNA Capital Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
DAFNA Capital Management LLC Q2 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Stereotaxis, Inc.March 08, 201813,680,55423.4%
SUNESIS PHARMACEUTICALS INCFebruary 14, 2018983,0002.9%
SUNESIS PHARMACEUTICALS INCFebruary 14, 20171,133,5835.4%
WINDTREE THERAPEUTICS INC /DE/February 14, 2017208,3332.4%
ANAVEX LIFE SCIENCES CORP.Sold outFebruary 16, 201600.0%
DISCOVERY LABORATORIES INC /DE/February 16, 201610,658,6999.2%
PRECISION OPTICS CORPORATION, INC.February 13, 2015311,5375.0%
TearLab CorpFebruary 14, 2013939,2393.2%
VIKING SYSTEMS INCFebruary 14, 20123,781,4685.2%

View DAFNA Capital Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
13F-HR2023-02-14
13F-HR2022-11-14

View DAFNA Capital Management LLC's complete filings history.

Compare quarters

Export DAFNA Capital Management LLC's holdings